Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Mutations in PI3K110δ cause impaired natural killer cell function partially rescued by rapamycin treatment.

Ruiz-García R, Vargas-Hernández A, Chinn IK, Angelo LS, Cao TN, Coban-Akdemir Z, Jhangiani SN, Meng Q, Forbes LR, Muzny DM, Allende LM, Ehlayel MS, Gibbs RA, Lupski JR, Uzel G, Orange JS, Mace EM.

J Allergy Clin Immunol. 2018 Jan 10. pii: S0091-6749(18)30026-5. doi: 10.1016/j.jaci.2017.11.042. [Epub ahead of print]

PMID:
29330011
2.

Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models.

Decker WK, da Silva RF, Sanabria MH, Angelo LS, Guimarães F, Burt BM, Kheradmand F, Paust S.

Front Immunol. 2017 Aug 2;8:829. doi: 10.3389/fimmu.2017.00829. eCollection 2017. Review.

3.

Biallelic mutations in IRF8 impair human NK cell maturation and function.

Mace EM, Bigley V, Gunesch JT, Chinn IK, Angelo LS, Care MA, Maisuria S, Keller MD, Togi S, Watkin LB, LaRosa DF, Jhangiani SN, Muzny DM, Stray-Pedersen A, Coban Akdemir Z, Smith JB, Hernández-Sanabria M, Le DT, Hogg GD, Cao TN, Freud AG, Szymanski EP, Savic S, Collin M, Cant AJ, Gibbs RA, Holland SM, Caligiuri MA, Ozato K, Paust S, Doody GM, Lupski JR, Orange JS.

J Clin Invest. 2017 Jan 3;127(1):306-320. doi: 10.1172/JCI86276. Epub 2016 Nov 28.

4.

Practical NK cell phenotyping and variability in healthy adults.

Angelo LS, Banerjee PP, Monaco-Shawver L, Rosen JB, Makedonas G, Forbes LR, Mace EM, Orange JS.

Immunol Res. 2015 Jul;62(3):341-56. doi: 10.1007/s12026-015-8664-y.

5.

Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab.

Falchook GS, Wheler JJ, Naing A, Jackson EF, Janku F, Hong D, Ng CS, Tannir NM, Lawhorn KN, Huang M, Angelo LS, Vishwamitra D, Hess K, Howard AN, Parkhurst KL, Amin HM, Kurzrock R.

Oncotarget. 2014 Nov 15;5(21):10280-92.

6.

Severe cutaneous human papillomavirus infection associated with natural killer cell deficiency following stem cell transplantation for severe combined immunodeficiency.

Kamili QUA, Seeborg FO, Saxena K, Nicholas SK, Banerjee PP, Angelo LS, Mace EM, Forbes LR, Martinez C, Wright TS, Orange JS, Hanson IC.

J Allergy Clin Immunol. 2014 Dec;134(6):1451-1453.e1. doi: 10.1016/j.jaci.2014.07.009. Epub 2014 Aug 23. No abstract available.

7.

The dopamine D2/D3 receptor agonist quinpirole increases checking-like behaviour in an operant observing response task with uncertain reinforcement: a novel possible model of OCD.

Eagle DM, Noschang C, d'Angelo LS, Noble CA, Day JO, Dongelmans ML, Theobald DE, Mar AC, Urcelay GP, Morein-Zamir S, Robbins TW.

Behav Brain Res. 2014 May 1;264:207-29. doi: 10.1016/j.bbr.2013.12.040. Epub 2014 Jan 6.

8.

NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations.

Schroeder RD, Angelo LS, Kurzrock R.

Oncotarget. 2014 Jan 15;5(1):67-77. Review.

9.

Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications.

Jiang Y, Janku F, Subbiah V, Angelo LS, Naing A, Anderson PM, Herzog CE, Fu S, Benjamin RS, Kurzrock R.

Oncotarget. 2013 Jun;4(6):884-9.

11.

Binding partners for curcumin in human schwannoma cells: biologic implications.

Angelo LS, Maxwell DS, Wu JY, Sun D, Hawke DH, McCutcheon IE, Slopis JM, Peng Z, Bornmann WG, Kurzrock R.

Bioorg Med Chem. 2013 Feb 15;21(4):932-9. doi: 10.1016/j.bmc.2012.12.008. Epub 2012 Dec 13.

PMID:
23294827
12.

R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis.

Huang HJ, Angelo LS, Rodon J, Sun M, Kuenkele KP, Parsons HA, Trent JC, Kurzrock R.

PLoS One. 2011;6(10):e26060. doi: 10.1371/journal.pone.0026060. Epub 2011 Oct 11.

13.

Insulin-like growth factor 1 receptor (IGF-1R) inhibitor: another arrow in the quiver - Will it hit the moving target?

Subbiah V, Angelo LS, Kurzrock R.

Expert Opin Investig Drugs. 2011 Nov;20(11):1471-7. doi: 10.1517/13543784.2011.619978. Epub 2011 Sep 21.

PMID:
21936711
14.

Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathways.

Angelo LS, Wu JY, Meng F, Sun M, Kopetz S, McCutcheon IE, Slopis JM, Kurzrock R.

Mol Cancer Ther. 2011 Nov;10(11):2094-103. doi: 10.1158/1535-7163.MCT-11-0243. Epub 2011 Sep 8.

15.

Target validation using Phase 0 clinical trials: Promises and pitfalls.

Angelo LS, Kurzrock R.

Cancer Biol Ther. 2009 Nov;8(21):2010-2. No abstract available.

PMID:
20037466
16.

Molecular imaging of gefitinib activity in an epidermal growth factor receptor (EGFR)-bearing xenograft model.

Gong J, Yang DJ, Kohanim S, Angelo LS, Kurzrock R.

Cancer Biol Ther. 2009 Dec;8(23):2239-47. Epub 2009 Dec 2.

PMID:
19823028
17.

Molecular imaging of Bcr-Abl phosphokinase in a xenograft model.

Wu JY, Yang DJ, Angelo LS, Kohanim S, Kurzrock R.

Mol Cancer Ther. 2009 Mar;8(3):703-10. doi: 10.1158/1535-7163.MCT-08-0656. Epub 2009 Mar 3.

18.

Turmeric and green tea: a recipe for the treatment of B-chronic lymphocytic leukemia.

Angelo LS, Kurzrock R.

Clin Cancer Res. 2009 Feb 15;15(4):1123-5. doi: 10.1158/1078-0432.CCR-08-2791.

19.

Interleukin-6 and its receptor in cancer: implications for translational therapeutics.

Hong DS, Angelo LS, Kurzrock R.

Cancer. 2007 Nov 1;110(9):1911-28. Review.

20.

Vascular endothelial growth factor and its relationship to inflammatory mediators.

Angelo LS, Kurzrock R.

Clin Cancer Res. 2007 May 15;13(10):2825-30. Review.

21.

Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53.

Angelo LS, Talpaz M, Kurzrock R.

Cancer Res. 2002 Feb 1;62(3):932-40.

22.

Selection, establishment and characterization of cell lines derived from a chemically-induced rat mammary heterogeneous tumor, by flow cytometry, transmission electron microscopy, and immunohistochemistry.

Teodori L, Tagliaferri F, Stipa F, Valente MG, Coletti D, Manganelli A, Guglielmi M, D'Angelo LS, Schäfer H, Göhde W.

In Vitro Cell Dev Biol Anim. 2000 Mar;36(3):153-62.

PMID:
10777054
23.

Formation of myointimal hyperplasia and cytokine production in experimental vein grafts.

Sterpetti AV, Cucina A, Lepidi S, Randone B, Corvino V, D'Angelo LS, Cavallaro A.

Surgery. 1998 Apr;123(4):461-9.

PMID:
9551074
24.

Shear stress induces transforming growth factor-beta 1 release by arterial endothelial cells.

Cucina A, Sterpetti AV, Borrelli V, Pagliei S, Cavallaro A, D'Angelo LS.

Surgery. 1998 Feb;123(2):212-7.

PMID:
9481408
25.

An anti-LFA-1 monoclonal antibody (LDA-8) induces cellular aggregation of human lymphoblastoid cell lines and peripheral blood lymphocytes.

Yang JS, Mathioudakis G, Kruzel E, Angelo LS, Sakkas LI, Lee JE, Oleszak EL, Platsoucas CD.

Hematopathol Mol Hematol. 1997-1998;11(1):29-40.

PMID:
9439978
26.

Progression and regression of myointimal hyperplasia in experimental vein grafts depends on platelet-derived growth factor and basic fibroblastic growth factor production.

Sterpetti AV, Cucina A, Lepidi S, Randone B, Stipa F, Aromatario C, Travi D, D'Angelo LS, Cavallaro A, Stipa S.

J Vasc Surg. 1996 Apr;23(4):568-75.

27.

The degree of porosity influences the release of growth factors by healing polytetrafluoroethylene (PTFE) grafts.

Lepidi S, Sterpetti AV, Cucina A, Randone B, Palumbo R, Patrizi AL, Stipa F, D'Angelo LS, Cavallaro A.

Eur J Vasc Endovasc Surg. 1996 Jan;11(1):36-41.

28.

Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis?

Owen-Schaub LB, Angelo LS, Radinsky R, Ware CF, Gesner TG, Bartos DP.

Cancer Lett. 1995 Jul 20;94(1):1-8.

PMID:
7542559
29.

Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression.

Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang WW, Kruzel E, et al.

Mol Cell Biol. 1995 Jun;15(6):3032-40.

30.

Shear stress increases the release of interleukin-1 and interleukin-6 by aortic endothelial cells.

Sterpetti AV, Cucina A, Morena AR, Di Donna S, D'Angelo LS, Cavalarro A, Stipa S.

Surgery. 1993 Nov;114(5):911-4.

PMID:
8236014
31.

Shear stress modulates the proliferation rate, protein synthesis, and mitogenic activity of arterial smooth muscle cells.

Sterpetti AV, Cucina A, D'Angelo LS, Cardillo B, Cavallaro A.

Surgery. 1993 Jun;113(6):691-9.

PMID:
8506528
32.

Growth factor release by smooth muscle cells is dependent on haemodynamic factors.

Sterpetti AV, Cucina A, Napoli F, Shafer H, Cavallaro A, D'Angelo LS.

Eur J Vasc Surg. 1992 Nov;6(6):636-8.

PMID:
1451820
33.

Response of arterial smooth muscle cells to laminar flow.

Sterpetti AV, Cucina A, D'Angelo LS, Cardillo B, Cavallaro A.

J Cardiovasc Surg (Torino). 1992 Sep-Oct;33(5):619-24.

PMID:
1447284
34.

Re: One-step purification of human monocytes by flotation from blood-Percoll mixtures.

D'Angelo LS, Rollier Mottura A, Alescio T, Pozzi L, Pasquali M, Siccardi AG, Gulluni Cuomo M.

J Immunol Methods. 1984 Aug 3;72(1):307-9. No abstract available.

PMID:
6086762
35.

Further investigations on the theratogenic effects of veratrin administered to the blastules of anuran amphibians.

Cuomo MG, D'Angelo LS, Baviera G.

Riv Biol. 1976 Jul-Dec;69(3-4):277-305. English, Italian. No abstract available.

PMID:
1088478
36.

Site and mechanism of uptake of 3H--norepinephrine by isolated perfused rat lungs.

Nicholas TE, Strum JM, Angelo LS, Junod AF.

Circ Res. 1974 Nov;35(5):670-80. No abstract available.

37.

[Immunological studies on malignant tumours in man. Methods and first results].

Pittoni G, D'Angelo LS, Cuomo M.

Riv Biol. 1970 Apr-Jun;63(2):167-219. Multiple languages. No abstract available.

PMID:
4990313

Supplemental Content

Loading ...
Support Center